Dendritic cell-targeted VLP vaccine for enhanced anti-tumor immunity
A novel glycan-costumed virus-like particle (VLP) vaccine targets dendritic cell lectins to elicit potent Type 1 anti-tumor responses. This approach enhances long-term tumor protection by activating specific T cell responses and inhibiting tumor growth.
Overview
The innovative dendritic cell-targeted VLP vaccine is an advanced immunotherapy solution designed to enhance anti-tumor immunity. This novel vaccine employs a unique glycan-costumed virus-like particle (VLP) approach to deliver antigens and TLR signals directly to dendritic cells (DCs). By targeting specific DC lectins, such as DC-SIGN, this vaccine stimulates potent Type 1 cellular immune responses crucial for tumor antigen-specific Th1 CD4+ and CD8+ T cell activation. The result is effective infiltration and inhibition of tumor growth, coupled with long-term durable protection against tumors.
Technical specifications
Key features:
- Utilizes glycan-costumed VLPs to engage dendritic cell lectins for enhanced immune activation
- Includes a TLR7 agonist (ssRNA) to potentiate immune responses
- Generates high levels of IFN-γ, promoting Th1 CD4+ and CD8+ T cell infiltration into tumors
- Demonstrates effectiveness in a syngeneic B16 melanoma model
- Offers long-term protection by inducing specific T cell memory responses
Technology readiness level
This dendritic cell-targeted VLP vaccine has reached Technology Readiness Level 3, indicating that it has been validated in a laboratory setting. Future research will focus on optimizing the vaccine with different antigens and lectins, and validating its efficacy in vivo, including assessments of tumor growth inhibition and immune response profiling.
About Massachusetts Institute of Technology
MIT is a private research university known for intensive, interdisciplinary discovery and a global scale of sponsored research. Industry engages through a long-standing corporate partnership program, on-campus collaboration spaces, and shared-use facilities that enable rapid prototyping and characterization. The institute also operates a federally funded R&D center and maintains close adjacency to Kendall Square, allowing company teams to embed with faculty and students and accelerate translation. Research is supported by competitive federal funding from NSF, NIH, DOE, and the Department of Defense. A dedicated technology transfer office, standardized agreements, and an affiliated deep-tech accelerator support IP, licensing, and startup formation.
delivered to your inbox.